Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Neoplasms 10Multiple Myeloma 8Prostatic Neoplasms 6Neoplasm Metastasis 5Giant Cell Tumor of Bone 5Fractures, Bone 4Recurrence 3Osteoporosis 3Bone Neoplasms 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Lymphoma 2Kidney Neoplasms 2Giant Cell Tumors 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Mastocytosis, Systemic 1Lymphoma, Non-Hodgkin 1

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1epothilone B 1cabazitaxel 1bafetinib 1Everolimus 1Denosumab 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hormone Refractory Prostate Cancer × Denosumab × Clear all
NCT00286091 2018-10-17

Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer

Amgen

Phase 3 Completed
1,435 enrolled 15 charts
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡